

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 November 2005 (03.11.2005)

PCT

(10) International Publication Number  
**WO 2005/101966 A2**

(51) International Patent Classification: Not classified

(21) International Application Number:  
PCT/IB2005/002424

(22) International Filing Date: 8 April 2005 (08.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/561,408 12 April 2004 (12.04.2004) US

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant and

(72) Inventor: NGU, Victor, Anomah [CM/CM]; P.O. Box 1364, Yaounde (CM).

Published:

— without international search report and to be republished upon receipt of that report

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: THERAPEUTIC VACCINE AND METHOD OF USE

(57) Abstract: A therapeutic vaccine is prepared by a method which includes the steps of extracting, with a lipid-extracting solvent, a biological fluid obtained from a person or animal infected with a lipid-containing infectious organism, the biological fluid containing the lipid-containing infectious organism, and the extraction producing an aqueous phase and a lipid-containing phase, said aqueous phase containing the infectious organism with the lipid substantially removed, and separating the aqueous phase from the lipid-containing phase. A leukocyte fraction is isolated from the blood of the person or animal, the isolation being conducted so that the leukocyte fraction is substantially without plasma, free lipid-containing infectious organism and free antibodies to the lipid-containing infectious organism, and at least some of the aqueous phase is combined with at least some of the leukocyte fraction to produce the vaccine.

WO 2005/101966 A2